nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—CYP2C19—Teniposide—lymphatic system cancer	0.159	0.546	CbGbCtD
Nilutamide—CYP2C9—Teniposide—lymphatic system cancer	0.132	0.454	CbGbCtD
Nilutamide—Pneumonia—Fludarabine—lymphatic system cancer	0.00523	0.00738	CcSEcCtD
Nilutamide—Blood urea increased—Mitoxantrone—lymphatic system cancer	0.00522	0.00737	CcSEcCtD
Nilutamide—Abnormal vision—Carmustine—lymphatic system cancer	0.00519	0.00733	CcSEcCtD
Nilutamide—Arthritis—Bleomycin—lymphatic system cancer	0.00509	0.00719	CcSEcCtD
Nilutamide—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00505	0.00714	CcSEcCtD
Nilutamide—Haematuria—Fludarabine—lymphatic system cancer	0.00496	0.007	CcSEcCtD
Nilutamide—Anorexia—Mechlorethamine—lymphatic system cancer	0.00488	0.00689	CcSEcCtD
Nilutamide—Alopecia—Teniposide—lymphatic system cancer	0.00469	0.00663	CcSEcCtD
Nilutamide—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00464	0.00656	CcSEcCtD
Nilutamide—Visual impairment—Fludarabine—lymphatic system cancer	0.0045	0.00635	CcSEcCtD
Nilutamide—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00445	0.00628	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00432	0.0061	CcSEcCtD
Nilutamide—Anaemia—Teniposide—lymphatic system cancer	0.00427	0.00603	CcSEcCtD
Nilutamide—Leukopenia—Teniposide—lymphatic system cancer	0.00414	0.00584	CcSEcCtD
Nilutamide—Alopecia—Fludarabine—lymphatic system cancer	0.00412	0.00582	CcSEcCtD
Nilutamide—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00411	0.00581	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00401	0.00567	CcSEcCtD
Nilutamide—Hypertension—Teniposide—lymphatic system cancer	0.00399	0.00564	CcSEcCtD
Nilutamide—Chest pain—Teniposide—lymphatic system cancer	0.00394	0.00556	CcSEcCtD
Nilutamide—Lung disorder—Methotrexate—lymphatic system cancer	0.00389	0.0055	CcSEcCtD
Nilutamide—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00389	0.0055	CcSEcCtD
Nilutamide—Weight decreased—Bleomycin—lymphatic system cancer	0.00387	0.00546	CcSEcCtD
Nilutamide—Pneumonia—Bleomycin—lymphatic system cancer	0.00383	0.00541	CcSEcCtD
Nilutamide—Oedema—Teniposide—lymphatic system cancer	0.00377	0.00533	CcSEcCtD
Nilutamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00377	0.00532	CcSEcCtD
Nilutamide—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00376	0.00531	CcSEcCtD
Nilutamide—Anaemia—Fludarabine—lymphatic system cancer	0.00376	0.0053	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00371	0.00524	CcSEcCtD
Nilutamide—Malaise—Fludarabine—lymphatic system cancer	0.00366	0.00517	CcSEcCtD
Nilutamide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00365	0.00515	CcSEcCtD
Nilutamide—Leukopenia—Fludarabine—lymphatic system cancer	0.00364	0.00514	CcSEcCtD
Nilutamide—Haematuria—Bleomycin—lymphatic system cancer	0.00363	0.00513	CcSEcCtD
Nilutamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00362	0.00511	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00361	0.0051	CcSEcCtD
Nilutamide—Anorexia—Teniposide—lymphatic system cancer	0.0036	0.00508	CcSEcCtD
Nilutamide—Cough—Fludarabine—lymphatic system cancer	0.00355	0.00501	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00354	0.005	CcSEcCtD
Nilutamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0035	0.00494	CcSEcCtD
Nilutamide—Discomfort—Fludarabine—lymphatic system cancer	0.00342	0.00483	CcSEcCtD
Nilutamide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.0034	0.00481	CcSEcCtD
Nilutamide—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00337	0.00475	CcSEcCtD
Nilutamide—Dyspnoea—Teniposide—lymphatic system cancer	0.00336	0.00475	CcSEcCtD
Nilutamide—Pneumonia—Carmustine—lymphatic system cancer	0.00335	0.00473	CcSEcCtD
Nilutamide—Depression—Carmustine—lymphatic system cancer	0.00332	0.00468	CcSEcCtD
Nilutamide—Oedema—Fludarabine—lymphatic system cancer	0.00332	0.00468	CcSEcCtD
Nilutamide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00328	0.00463	CcSEcCtD
Nilutamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00328	0.00463	CcSEcCtD
Nilutamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00325	0.00459	CcSEcCtD
Nilutamide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00323	0.00457	CcSEcCtD
Nilutamide—Rash—Mechlorethamine—lymphatic system cancer	0.00323	0.00456	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00322	0.00455	CcSEcCtD
Nilutamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00322	0.00455	CcSEcCtD
Nilutamide—Weight decreased—Vincristine—lymphatic system cancer	0.00322	0.00455	CcSEcCtD
Nilutamide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00321	0.00453	CcSEcCtD
Nilutamide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.0032	0.00451	CcSEcCtD
Nilutamide—Pneumonia—Vincristine—lymphatic system cancer	0.00319	0.00451	CcSEcCtD
Nilutamide—Depression—Vincristine—lymphatic system cancer	0.00317	0.00447	CcSEcCtD
Nilutamide—Anorexia—Fludarabine—lymphatic system cancer	0.00316	0.00446	CcSEcCtD
Nilutamide—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00314	0.00443	CcSEcCtD
Nilutamide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00313	0.00442	CcSEcCtD
Nilutamide—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00311	0.00439	CcSEcCtD
Nilutamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00311	0.00439	CcSEcCtD
Nilutamide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00309	0.00436	CcSEcCtD
Nilutamide—Sweating—Vincristine—lymphatic system cancer	0.00305	0.0043	CcSEcCtD
Nilutamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00304	0.00429	CcSEcCtD
Nilutamide—Alopecia—Bleomycin—lymphatic system cancer	0.00302	0.00427	CcSEcCtD
Nilutamide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00301	0.00425	CcSEcCtD
Nilutamide—Abdominal pain—Teniposide—lymphatic system cancer	0.00298	0.00421	CcSEcCtD
Nilutamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00298	0.00421	CcSEcCtD
Nilutamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00298	0.0042	CcSEcCtD
Nilutamide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00297	0.0042	CcSEcCtD
Nilutamide—Sweating—Mitoxantrone—lymphatic system cancer	0.00297	0.00419	CcSEcCtD
Nilutamide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00296	0.00417	CcSEcCtD
Nilutamide—Haematuria—Mitoxantrone—lymphatic system cancer	0.00295	0.00416	CcSEcCtD
Nilutamide—Oedema peripheral—Carmustine—lymphatic system cancer	0.00294	0.00416	CcSEcCtD
Nilutamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00292	0.00412	CcSEcCtD
Nilutamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00288	0.00407	CcSEcCtD
Nilutamide—Visual impairment—Carmustine—lymphatic system cancer	0.00288	0.00406	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00286	0.00404	CcSEcCtD
Nilutamide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00284	0.00401	CcSEcCtD
Nilutamide—Pain—Fludarabine—lymphatic system cancer	0.00284	0.004	CcSEcCtD
Nilutamide—Constipation—Fludarabine—lymphatic system cancer	0.00284	0.004	CcSEcCtD
Nilutamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00282	0.00398	CcSEcCtD
Nilutamide—Urethral disorder—Vincristine—lymphatic system cancer	0.0028	0.00395	CcSEcCtD
Nilutamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00278	0.00393	CcSEcCtD
Nilutamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00276	0.0039	CcSEcCtD
Nilutamide—Anaemia—Bleomycin—lymphatic system cancer	0.00275	0.00389	CcSEcCtD
Nilutamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00273	0.00386	CcSEcCtD
Nilutamide—Asthenia—Teniposide—lymphatic system cancer	0.00271	0.00382	CcSEcCtD
Nilutamide—Melaena—Methotrexate—lymphatic system cancer	0.00269	0.0038	CcSEcCtD
Nilutamide—Malaise—Bleomycin—lymphatic system cancer	0.00269	0.00379	CcSEcCtD
Nilutamide—Pruritus—Teniposide—lymphatic system cancer	0.00267	0.00377	CcSEcCtD
Nilutamide—Leukopenia—Bleomycin—lymphatic system cancer	0.00267	0.00377	CcSEcCtD
Nilutamide—Alopecia—Carmustine—lymphatic system cancer	0.00264	0.00373	CcSEcCtD
Nilutamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00262	0.0037	CcSEcCtD
Nilutamide—Cough—Bleomycin—lymphatic system cancer	0.0026	0.00367	CcSEcCtD
Nilutamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00258	0.00365	CcSEcCtD
Nilutamide—Chest pain—Bleomycin—lymphatic system cancer	0.00254	0.00358	CcSEcCtD
Nilutamide—Alopecia—Vincristine—lymphatic system cancer	0.00252	0.00356	CcSEcCtD
Nilutamide—Back pain—Carmustine—lymphatic system cancer	0.00252	0.00355	CcSEcCtD
Nilutamide—Discomfort—Bleomycin—lymphatic system cancer	0.00251	0.00354	CcSEcCtD
Nilutamide—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00247	0.00348	CcSEcCtD
Nilutamide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00245	0.00347	CcSEcCtD
Nilutamide—Oedema—Bleomycin—lymphatic system cancer	0.00243	0.00343	CcSEcCtD
Nilutamide—Anaemia—Carmustine—lymphatic system cancer	0.0024	0.00339	CcSEcCtD
Nilutamide—Back pain—Vincristine—lymphatic system cancer	0.0024	0.00339	CcSEcCtD
Nilutamide—Vomiting—Teniposide—lymphatic system cancer	0.0024	0.00339	CcSEcCtD
Nilutamide—Asthenia—Fludarabine—lymphatic system cancer	0.00238	0.00336	CcSEcCtD
Nilutamide—Rash—Teniposide—lymphatic system cancer	0.00238	0.00336	CcSEcCtD
Nilutamide—Dermatitis—Teniposide—lymphatic system cancer	0.00238	0.00336	CcSEcCtD
Nilutamide—Headache—Teniposide—lymphatic system cancer	0.00236	0.00334	CcSEcCtD
Nilutamide—Pruritus—Fludarabine—lymphatic system cancer	0.00235	0.00331	CcSEcCtD
Nilutamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00234	0.0033	CcSEcCtD
Nilutamide—Leukopenia—Carmustine—lymphatic system cancer	0.00233	0.00329	CcSEcCtD
Nilutamide—Anorexia—Bleomycin—lymphatic system cancer	0.00232	0.00327	CcSEcCtD
Nilutamide—Anaemia—Vincristine—lymphatic system cancer	0.00229	0.00324	CcSEcCtD
Nilutamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00227	0.0032	CcSEcCtD
Nilutamide—Hypertension—Carmustine—lymphatic system cancer	0.00224	0.00317	CcSEcCtD
Nilutamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00224	0.00317	CcSEcCtD
Nilutamide—Nausea—Teniposide—lymphatic system cancer	0.00224	0.00316	CcSEcCtD
Nilutamide—Anaemia—Mitoxantrone—lymphatic system cancer	0.00223	0.00315	CcSEcCtD
Nilutamide—Leukopenia—Vincristine—lymphatic system cancer	0.00222	0.00314	CcSEcCtD
Nilutamide—Chest pain—Carmustine—lymphatic system cancer	0.00221	0.00313	CcSEcCtD
Nilutamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00218	0.00308	CcSEcCtD
Nilutamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00218	0.00308	CcSEcCtD
Nilutamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00217	0.00306	CcSEcCtD
Nilutamide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00216	0.00306	CcSEcCtD
Nilutamide—Hypertension—Vincristine—lymphatic system cancer	0.00214	0.00303	CcSEcCtD
Nilutamide—Oedema—Carmustine—lymphatic system cancer	0.00212	0.003	CcSEcCtD
Nilutamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00211	0.00298	CcSEcCtD
Nilutamide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00211	0.00298	CcSEcCtD
Nilutamide—Cough—Mitoxantrone—lymphatic system cancer	0.00211	0.00298	CcSEcCtD
Nilutamide—Vomiting—Fludarabine—lymphatic system cancer	0.00211	0.00298	CcSEcCtD
Nilutamide—Rash—Fludarabine—lymphatic system cancer	0.00209	0.00295	CcSEcCtD
Nilutamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00209	0.00295	CcSEcCtD
Nilutamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00209	0.00295	CcSEcCtD
Nilutamide—Pain—Bleomycin—lymphatic system cancer	0.00208	0.00294	CcSEcCtD
Nilutamide—Headache—Fludarabine—lymphatic system cancer	0.00208	0.00293	CcSEcCtD
Nilutamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00206	0.00291	CcSEcCtD
Nilutamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00203	0.00287	CcSEcCtD
Nilutamide—Oedema—Vincristine—lymphatic system cancer	0.00203	0.00286	CcSEcCtD
Nilutamide—Anorexia—Carmustine—lymphatic system cancer	0.00202	0.00286	CcSEcCtD
Nilutamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.002	0.00283	CcSEcCtD
Nilutamide—Oedema—Mitoxantrone—lymphatic system cancer	0.00197	0.00279	CcSEcCtD
Nilutamide—Nausea—Fludarabine—lymphatic system cancer	0.00197	0.00278	CcSEcCtD
Nilutamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00196	0.00277	CcSEcCtD
Nilutamide—Shock—Mitoxantrone—lymphatic system cancer	0.00194	0.00274	CcSEcCtD
Nilutamide—Anorexia—Vincristine—lymphatic system cancer	0.00193	0.00273	CcSEcCtD
Nilutamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00192	0.00271	CcSEcCtD
Nilutamide—Insomnia—Carmustine—lymphatic system cancer	0.00192	0.00271	CcSEcCtD
Nilutamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00191	0.00269	CcSEcCtD
Nilutamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00191	0.00269	CcSEcCtD
Nilutamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00189	0.00267	CcSEcCtD
Nilutamide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00188	0.00266	CcSEcCtD
Nilutamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00184	0.0026	CcSEcCtD
Nilutamide—Insomnia—Vincristine—lymphatic system cancer	0.00183	0.00259	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00183	0.00259	CcSEcCtD
Nilutamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00182	0.00257	CcSEcCtD
Nilutamide—Pain—Carmustine—lymphatic system cancer	0.00181	0.00256	CcSEcCtD
Nilutamide—Constipation—Carmustine—lymphatic system cancer	0.00181	0.00256	CcSEcCtD
Nilutamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00177	0.0025	CcSEcCtD
Nilutamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00176	0.00249	CcSEcCtD
Nilutamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00176	0.00248	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00175	0.00247	CcSEcCtD
Nilutamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00175	0.00247	CcSEcCtD
Nilutamide—Asthenia—Bleomycin—lymphatic system cancer	0.00174	0.00246	CcSEcCtD
Nilutamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00174	0.00245	CcSEcCtD
Nilutamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00174	0.00245	CcSEcCtD
Nilutamide—Constipation—Vincristine—lymphatic system cancer	0.00173	0.00245	CcSEcCtD
Nilutamide—Pain—Vincristine—lymphatic system cancer	0.00173	0.00245	CcSEcCtD
Nilutamide—Pruritus—Bleomycin—lymphatic system cancer	0.00172	0.00243	CcSEcCtD
Nilutamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00172	0.00242	CcSEcCtD
Nilutamide—Pain—Mitoxantrone—lymphatic system cancer	0.00169	0.00238	CcSEcCtD
Nilutamide—Constipation—Mitoxantrone—lymphatic system cancer	0.00169	0.00238	CcSEcCtD
Nilutamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00168	0.00237	CcSEcCtD
Nilutamide—Abdominal pain—Carmustine—lymphatic system cancer	0.00168	0.00237	CcSEcCtD
Nilutamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00166	0.00234	CcSEcCtD
Nilutamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00163	0.0023	CcSEcCtD
Nilutamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00161	0.00228	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00161	0.00227	CcSEcCtD
Nilutamide—Body temperature increased—Vincristine—lymphatic system cancer	0.0016	0.00226	CcSEcCtD
Nilutamide—Abdominal pain—Vincristine—lymphatic system cancer	0.0016	0.00226	CcSEcCtD
Nilutamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00159	0.00225	CcSEcCtD
Nilutamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00156	0.0022	CcSEcCtD
Nilutamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00156	0.0022	CcSEcCtD
Nilutamide—Pneumonia—Methotrexate—lymphatic system cancer	0.00155	0.00219	CcSEcCtD
Nilutamide—Vomiting—Bleomycin—lymphatic system cancer	0.00155	0.00218	CcSEcCtD
Nilutamide—Depression—Methotrexate—lymphatic system cancer	0.00154	0.00217	CcSEcCtD
Nilutamide—Rash—Bleomycin—lymphatic system cancer	0.00153	0.00216	CcSEcCtD
Nilutamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00153	0.00216	CcSEcCtD
Nilutamide—Asthenia—Carmustine—lymphatic system cancer	0.00152	0.00215	CcSEcCtD
Nilutamide—Sweating—Methotrexate—lymphatic system cancer	0.00148	0.00209	CcSEcCtD
Nilutamide—Haematuria—Methotrexate—lymphatic system cancer	0.00147	0.00208	CcSEcCtD
Nilutamide—Asthenia—Vincristine—lymphatic system cancer	0.00145	0.00205	CcSEcCtD
Nilutamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00145	0.00205	CcSEcCtD
Nilutamide—Nausea—Bleomycin—lymphatic system cancer	0.00144	0.00204	CcSEcCtD
Nilutamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00142	0.002	CcSEcCtD
Nilutamide—Dizziness—Carmustine—lymphatic system cancer	0.0014	0.00198	CcSEcCtD
Nilutamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00139	0.00196	CcSEcCtD
Nilutamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00137	0.00193	CcSEcCtD
Nilutamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00136	0.00192	CcSEcCtD
Nilutamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00135	0.00191	CcSEcCtD
Nilutamide—Vomiting—Carmustine—lymphatic system cancer	0.00135	0.00191	CcSEcCtD
Nilutamide—Dizziness—Vincristine—lymphatic system cancer	0.00134	0.00189	CcSEcCtD
Nilutamide—Rash—Carmustine—lymphatic system cancer	0.00134	0.00189	CcSEcCtD
Nilutamide—Dermatitis—Carmustine—lymphatic system cancer	0.00134	0.00189	CcSEcCtD
Nilutamide—Visual impairment—Methotrexate—lymphatic system cancer	0.00133	0.00188	CcSEcCtD
Nilutamide—Headache—Carmustine—lymphatic system cancer	0.00133	0.00188	CcSEcCtD
Nilutamide—Vomiting—Vincristine—lymphatic system cancer	0.00129	0.00182	CcSEcCtD
Nilutamide—Rash—Vincristine—lymphatic system cancer	0.00128	0.0018	CcSEcCtD
Nilutamide—Dermatitis—Vincristine—lymphatic system cancer	0.00128	0.0018	CcSEcCtD
Nilutamide—Headache—Vincristine—lymphatic system cancer	0.00127	0.00179	CcSEcCtD
Nilutamide—Nausea—Carmustine—lymphatic system cancer	0.00126	0.00178	CcSEcCtD
Nilutamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00125	0.00177	CcSEcCtD
Nilutamide—Rash—Mitoxantrone—lymphatic system cancer	0.00124	0.00176	CcSEcCtD
Nilutamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00124	0.00175	CcSEcCtD
Nilutamide—Headache—Mitoxantrone—lymphatic system cancer	0.00124	0.00175	CcSEcCtD
Nilutamide—Alopecia—Methotrexate—lymphatic system cancer	0.00122	0.00173	CcSEcCtD
Nilutamide—Nausea—Vincristine—lymphatic system cancer	0.0012	0.0017	CcSEcCtD
Nilutamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00117	0.00165	CcSEcCtD
Nilutamide—Back pain—Methotrexate—lymphatic system cancer	0.00117	0.00165	CcSEcCtD
Nilutamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00112	0.00158	CcSEcCtD
Nilutamide—Anaemia—Methotrexate—lymphatic system cancer	0.00111	0.00157	CcSEcCtD
Nilutamide—Malaise—Methotrexate—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Nilutamide—Leukopenia—Methotrexate—lymphatic system cancer	0.00108	0.00152	CcSEcCtD
Nilutamide—Cough—Methotrexate—lymphatic system cancer	0.00105	0.00148	CcSEcCtD
Nilutamide—Chest pain—Methotrexate—lymphatic system cancer	0.00103	0.00145	CcSEcCtD
Nilutamide—Discomfort—Methotrexate—lymphatic system cancer	0.00101	0.00143	CcSEcCtD
Nilutamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00095	0.00134	CcSEcCtD
Nilutamide—Anorexia—Methotrexate—lymphatic system cancer	0.000937	0.00132	CcSEcCtD
Nilutamide—Insomnia—Methotrexate—lymphatic system cancer	0.000889	0.00126	CcSEcCtD
Nilutamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000883	0.00125	CcSEcCtD
Nilutamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000876	0.00124	CcSEcCtD
Nilutamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000865	0.00122	CcSEcCtD
Nilutamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000854	0.00121	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000849	0.0012	CcSEcCtD
Nilutamide—Pain—Methotrexate—lymphatic system cancer	0.000841	0.00119	CcSEcCtD
Nilutamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00081	0.00114	CcSEcCtD
Nilutamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000804	0.00114	CcSEcCtD
Nilutamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000777	0.0011	CcSEcCtD
Nilutamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000777	0.0011	CcSEcCtD
Nilutamide—Asthenia—Methotrexate—lymphatic system cancer	0.000705	0.000996	CcSEcCtD
Nilutamide—Pruritus—Methotrexate—lymphatic system cancer	0.000695	0.000982	CcSEcCtD
Nilutamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000673	0.00095	CcSEcCtD
Nilutamide—Dizziness—Methotrexate—lymphatic system cancer	0.00065	0.000918	CcSEcCtD
Nilutamide—Vomiting—Methotrexate—lymphatic system cancer	0.000625	0.000883	CcSEcCtD
Nilutamide—Rash—Methotrexate—lymphatic system cancer	0.00062	0.000875	CcSEcCtD
Nilutamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000619	0.000874	CcSEcCtD
Nilutamide—Headache—Methotrexate—lymphatic system cancer	0.000616	0.00087	CcSEcCtD
Nilutamide—Nausea—Methotrexate—lymphatic system cancer	0.000584	0.000824	CcSEcCtD
